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Background: Development of resistance to conventional drugs and novel biological agents often impair long-term
chemotherapy. HMGA gene overexpression is often associated with antineoplastic drug resistance and reduced survival.
Inhibition of HMGA expression in thyroid cancer cells reduces levels of ATM protein, the main cellular sensor of DNA
damage, and enhances cellular sensitivity to DNA-damaging agents. HMGA1 overexpression promotes chemoresistance
to gemcitabine in pancreatic adenocarcinoma cells through an Akt-dependent mechanism.
Methods: To elucidate the role of HMGA1 proteins in chemoresistance we analyzed resistance to conventional drugs
and targeted therapies of human colon carcinoma cells (GEO) that are sensitive to the epidermal growth factor
receptor inhibitor cetuximab, and express minimal levels of HMGA1 and cetuximab-resistant (GEO CR) cells expressing
high HMGA1 protein levels.
Results: GEO CR cells were less sensitive than GEO cells to cetuximab and 5-fluorouracil. GEO CR cells silenced for
HMGA1 expression were more susceptible than empty vector-transfected cells to the drugs’ cytotoxicity. Similar results
were obtained with anaplastic thyroid carcinoma cells expressing or not HMGA1 proteins, treated with doxorubicin or
the HDAC inhibitor LBH589. Finally, HMGA1 overexpression promoted the DNA-damage response and stimulated Akt
phosphorylation and prosurvival signaling.
Conclusions: Our findings suggest that the blockage of HMGA1 expression is a promising approach to enhance
cancer cell chemosensitivity, since it could increase the sensitivity of cancer cells to antineoplastic drugs by inhibiting
the survival signal and DNA damage repair pathways.
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Chemotherapy is one of the most effective tools for the
treatment of neoplastic diseases, but it has two relevant
drawbacks: 1) it can harm normal cells, and 2) relapse
often occurs within 5 years, and recurrent disease is fre-
quently much more resistant to chemotherapy. The ad-
vent of new drugs that selectively target specific molecular
pathways involved in tumorigenesis or tumor progression,
known as “targeted therapy”, has improved patient out-
come and survival. However, both conventional chemo-
therapy and targeted therapies can fail because of acquired* Correspondence: daniela.dangelo@unina.it; alfusco@unina.it
1Dipartimento di Medicina Molecolare e Biotecnologie Mediche, Istituto di
Endocrinologia ed Oncologia Sperimentale del CNR c/o, Università di Napoli
Federico II, Via Pansini 5, 80131 Naples, Italy
Full list of author information is available at the end of the article
© 2014 D’Angelo et al.; licensee BioMed Centr
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.drug resistance. Several mechanisms alone or in combin-
ation can confer resistance to cancer cells, namely amplifi-
cation of cell survival signal pathways, increased DNA
damage repair, and altered cellular drug uptake, efflux or
metabolism [1,2]. However, each mechanism only partially
justifies the lack of response observed in cancer patients.
Thus, the identification of other mechanisms mediating
drug resistance is a challenge of oncological research.
High Mobility Group A (HMGAs) proteins are small
non-histone chromatin factors that bind the minor
groove of AT-rich DNA sequences through three N-
terminal basic domains called “AT-hooks”. The HMGA
family consists of four members: HMGA1a, HMGA1b
and HMGA1c (which are encoded through alternative
splicing by the HMGA1 gene) and HMGA2 (encoded byal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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during embryogenesis, and low or absent in normal
adult tissues. They are overexpressed in almost all hu-
man malignant neoplasias, often associated with metas-
tases and a poor prognosis [3]. HMGA proteins play a
key role in chemoresistance. Indeed, HMGA2 exhibits
dRP/AP site cleavage activity and protects cancer cells
from DNA-damage-induced cytotoxicity during chemo-
therapy [5]. HMGA1 overexpression promotes chemoresis-
tance to gemcitabine in pancreatic adenocarcinoma cells
in vitro through an Akt-dependent mechanism. Moreover,
HMGA1-silencing promotes gemcitabine-induced cytoxi-
city and reduces tumor growth in vivo in a nude mouse
xenograft model of pancreatic cancer [6].
Our group also demonstrated the involvement of
HMGAs in the pathway of Ataxia-Teleangiectasia-
Mutated (ATM) protein, the main cellular sensor of
DNA damage. We demonstrated that HMGA proteins
positively regulate ATM expression and the inhibition
of HMGA1 expression through an antisense approach
drastically decreases cellular levels of ATM in anaplas-
tic thyroid cancer (ATC) cells, resulting in increased
sensitivity to genotoxic agents [7].
To determine the role of HMGA1 proteins in che-
moresistance we have analyzed the resistance to anti-
neoplastic drugs of (i) the human colon carcinoma cells
(GEO) that are sensitive to the epidermal growth factor
receptor (EGFR) inhibitors cetuximab (CTX) and gefitinib,
and that express barely detectable levels of HMGA1, and
(ii) CTX-resistant GEO (GEO CR) cells that express high
HMGA1 protein levels and are generated through in vivo
continuous treatment with the drug followed by tumor ex-
plant and in vitro stabilization of the deriving resistant
cancer cell lines [8].
Methods
Drugs and treatment
Cetuximab was purchased from ImClone Systems.
Doxorubicin and 5-Fluorouracil were purchased from
Sigma (Sigma Aldrich, St Louis, MO, USA).
LBH589 was kindly provided by Dr. Caraglia. For ATM
inhibition experiments, cells were treated with KU-55933
(Calbiochem) (10 μM) for 1 h before the induction of
ATM kinase activity.Cell lines, expression vector and transfection
Human GEO and SW48 colon cancer cells and FRO
thyroid anaplastic carcinoma cells were from the American
Type Culture Collection (Manassas, VA, USA). GEO CR
(CTX resistant) cells were established as described previ-
ously [9]. Hairpin RNA interference plasmids were from
The RNAi Consortium (Sigma Aldrich). The control
PLKO.1 plasmid, which has a scrambled non-targetingshort-hairpin (sh) RNA sequence, was from SIGMA.
FRO shHMGA1, GEO CR shHMGA1 and respective sh
NoTargeting control stable clones were generated by
transfection of the above indicated plasmids using the
Neon™ Transfection System (Life Technologies, Carlsbad,
California). The pCEFLHA and the pCEFLHA-HMGA1,
vectors are described elsewhere [10]. GEO pCEFL-HA,
GEO-HMGA1, SW48 pCEFL-HA and SW48-HMGA1
cells were generated by transfection of the above-indicated
plasmids using the Neon™ Transfection System.
Cells were transfected using Neon™ Transfection System
(Life Technologies, Carlsbad, California) under the follow-
ing conditions:
FRO: Pulse voltage (v): 1450, Pulse Width (ms): 10,
Pulse number: 3;
GEO and SW48: Pulse voltage (v): 1300, Pulse Width
(ms): 30, Pulse number: 1.
After transfection, stable clones were selected by ex-
posure to 1 μg/ml of puromycin (GEO CR and FRO) or
800 ng/ml of neomycin (GEO and SW48) in complete
medium.
Protein extraction, western blotting and antibodies
Cells were lysed in lysis buffer containing 1% NP40, 1mM
EDTA, 50mM Tris–HCl (pH 7.5) and 150mM NaCl,
supplemented with complete protease inhibitors mixture
(Roche, Branford, CT, USA). Total proteins were separated
by SDS–polyacrylamide gel electrophoresis and transferred
to nitrocellulose membranes (Amersham, Piscataway, NJ,
USA). Membranes were blocked with 5% non-fat dry milk
and incubated with the following antibodies: anti-HMGA1
polyclonal antibody, as previously described [10], anti-
ATM S1981p (Rockland, Philadelphia, PA, USA), anti-
ATM (Ab91) (Abcam Cambridge, MA) β-actin (Santa
Cruz Biotechnology, Santa Cruz, CA, USA), (SC-1615;
Santa Cruz), anti-Akt, anti Akt S473p and Phospho-p70 S6
Kinase (Thr389) (Cell Signaling, Beverly, MA, USA), anti
Caspase-3 (Santa Cruz), anti-phospho-H2AX (ser 139)
(Upstate Biotechnology, Lake Placid, NY, USA).RNA extraction and quantitative-RT-PCR
Total RNA was isolated using TRI-reagent solution
(Sigma) and reverse transcription was performed ac-
cording to standard procedures (Qiagen, Valencia, CA,




β-actin Fw: 5′- CCAACCGCGAGAAGATGA-3;
β-actin Rv: 5′-CCAGAGGCGTACAGGGATAG -3.
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data. To calculate the relative expression levels we used
the 2-ΔΔCT method [11].Cell viability assay
Drug-induced cytotoxicity was quantified by MTS
(3-(4,5 dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl-
2-(4-sulfophenyl)-2H-tetrazolium) assay (Promega’s Cell-
Titer® 96 AQueous One Solution, Promega Fitchburg, WI,
USA). Cells were seeded in 96-well plates at 5×103 cells
per well, then exposed to serial dilutions of the drugs.
After 72h absorbance was measured at 490 nm.Apoptosis assays
Cells were treated with 5FU or doxorubicin and apop-
tosis was quantified by measuring Caspase 3/7 activation
using the Caspase-Glo 3/7 assay (Promega).Figure 1 HMGA1 overexpression is related to resistance to Cetuximab
analysis of protein extracts from GEO and GEO CR (Cetuximab Resistant) cells,
(Left Panel). qRT-PCR analysis of HMGA1 mRNA in GEO and GEO CR cells. Rela
expression levels between GEO and GEO CR, normalized with β-actin. The err
performed in triplicate (Right Panel). (B) Dose response curve for GEO and GE
Panel). Cells were exposed to the indicated doses of drugs and, after 72 h, ab
cell viability. The results are expressed as percent relative to the control. Value
response curves were obtained by non-linear curve fitting using GraphPad Pr
function. *p < 0.05 significance level compared with GEO cells. (C) IC50, inhibi
calculated as IC50 GEO CR/IC50 GEO cell line.Comet assay
Cells were treated with CTX and allowed to repair the
DNA for 0, 18 and 24 hours and then processed for the
COMET assay (Trevigen, Helgerman, CT, USA) following
manufacturer’s instructions. Cell images were analyzed
using COMET Score (TriTek, Annandale, VA, USA).
Comet tail moment was used as the measure of DNA
damage. In each experiment, 50 comets were measured
per experimental point and the mean ± S.D. was reported.Statistical analysis
We used two-way analysis of variance to compare inter-
group differences. The significance of differences was de-
termined by analysis of variances followed by Dunnett’s
test as post hoc test using Graph Pad Prism 5.0. Data are
reported as mean ± SD and p <0.05 was accepted as statis-
tically significant.and 5-Fluorouracil in GEO colon carcinoma cells. (A) Western blot
using HMGA1 and β-actin antibodies. β-Actin was used as loading control
tive expression values indicate the relative change in HMGA1 mRNA
or bars represent the mean ± S.D. of three independent experiments
O CR cells treated with cetuximab (Left Panel) or 5-fluorouracil (Right
sorbance at 490 nm was measured using a microplate reader to evaluate
s are the mean ± S.D. of three experiments performed in triplicate. Dose
ism 5.0. program. Note that the concentration is shown as logarithmic
tory concentration that kills 50% of cell population and Resistance index
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HMGA1 overexpression correlates with increased
resistance to drug-induced cytotoxicity
To define the role of HMGA1 in intrinsic and acquired
resistance to conventional and biological agents used in
cancer therapy, we first analyzed the sensitivity of GEO
colon carcinoma cells, showing a very low HMGA1 ex-
pression, and of GEO CR cells, expressing abundant
HMGA1 levels (Figure 1A), to the antineoplastic drugs
CTX and 5-fluorouracil (5FU), which are used to treat
colon cancer [8]. As shown in Figure 1C the GEO CR
cells were significantly less sensitive than GEO cells to
the cytotoxic effect exerted by CTX and 5FU. To deter-
mine whether this difference was due to differences inFigure 2 HMGA1 overexpression or silencing modulate the sensitivity
with a construct expressing the HMGA1 gene (GEO-HMGA1) or with empty
and β-actin antibodies. β-Actin was used as loading control (Left Panel). qR
cells. Relative expression values indicate the relative change in HMGA1 mR
normalized with β-actin (Right Panel). The error bars represent the mean ±
CR stably transfected with a short hairpin RNA targeting the HMGA1 gene
by western blot using HMGA1 and β-actin antibodies. β-Actin was used as
CR pLKO.1 and GEO CR shHMGA1. Relative expression values indicate the r
pLKO.1 and GEO CR shHMGA1, normalized with β-actin, assuming that the
bars represent the mean ± S.D. of three independent experiments performe
HMGA1 (C) and GEO CR pLKO.1 and GEO CR shHMGA1 (D) cells treated w
mean ± S.D. of three experiments performed in triplicate.The curves were fi
concentration is shown as logarithmic function. *p < 0.05 versus empty vec
inhibitory concentration that kills 50% of cell population and Resistance ind
(E) or IC50 GEO CR pLKO.1/ IC50 GEO CR shHMGA1.the expression of HMGA1, we stably overexpressed
HMGA1 in GEO cells by transfecting them with a con-
struct expressing HMGA1b isoform (GEO-HMGA1
cells) (Figure 2A), and silenced HMGA1 expression in
GEO CR cells by transfecting them with a short hairpin
RNA (shRNA) targeting the HMGA1 gene (GEO CR
shHMGA1 cells) (Figure 2B). As shown in Figure 2C,
GEO-HMGA1 cells were less sensitive to CTX and 5FU
than GEO cells transfected with empty vector (GEO
pCEFL-HA). Consistently, GEO CR shHMGA1 cells
were more susceptible than GEO CR transfected with a
scrambled no-targeting shRNA (GEO CR pLKO.1 cells).
Moreover, we examined the sensitivity to these drugs
of the colon carcinoma cell line, SW48, which expressesto cetuximab and 5-fluorouracil. (A) GEO cells stably transfected
vector (GEO pCEFL-HA) and analyzed by western blot using HMGA1
T-PCR analysis of HMGA1 mRNA in GEO pCEFL-HA and GEO-HMGA1
NA expression levels between GEO pCEFL-HA and GEO-HMGA1 and
S.D. of three independent experiments performed in triplicate. (B) GEO
(GEO CR shHMGA1) or the empty vector (GEO CR pLKO.1) and analyzed
loading control (Left Panel). qRT-PCR analysis of HMGA1 mRNA in GEO
elative change in HMGA1 mRNA expression levels between GEO CR
mean value of GEO CR pLKO.1 was equal to 1 (Right Panel). The error
d in triplicate. (C-D) Cell viability assay of GEO pCEFL-HA and GEO-
ith increasing doses of cetuximab or 5-fluorouracil. Values are the
tted using nonlinear regression (Graph Pad Prism 5.0. program). The
tor-transfected cells (GEO pCEFL-HA or GEO CR pLKO.1). (E-F) IC50,
ex calculated as IC50 GEO-HMGA1 /IC50 GEO pCEFL-HA cell line
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HMGA1) (Additional file 1: Figure S1A). As shown in
Additional file 1: Figure S1B, SW48-HMGA1 cells were
more resistant to the effect of CTX and 5FU than the
empty-vector-transfected SW48 cells (SW48 pCEFL-
HA cells).
We extended this analysis to FRO cells that derive from
a human anaplastic thyroid carcinoma. We transfected
these cells with the same construct used to silence
HMGA1 in GEO CR cells (FRO shHMGA1) (Figure 3A).
We then treated the FRO cells transfected with the empty
vector (FRO pKLO.1) and FRO shHMGA1 cells with
doxorubicin, that is currently used in the treatment of ana-
plastic thyroid carcinoma [12] and LBH589 (aka Panobino-
stat), an inhibitor of HDAC proteins currently undergoing
a clinical trial in patients with metastatic medullary thyroid
cancer or radioiodine-resistant differentiated thyroid can-
cer (ClinicalTrials.gov Identifier:NCT01013597). Also in
this case, cells overexpressing HMGA1 were more resistantFigure 3 HMGA1 silencing modulates the sensitivity to doxorubicin a
transfected with a short hairpin RNA targeting the HMGA1 gene (FRO shHM
antibodies. β-Actin was used as loading control (Left Panel). qRT-PCR analy
expression values indicate the relative change in HMGA1 mRNA expression
β-actin, assuming that the mean value of FRO pLKO.1 was equal to 1. (Righ
experiments performed in triplicate. (B) Cell viability assay of FRO pLKO.1 a
LBH-589 (Right Panel). Cells were exposed to the indicated doses of drugs
the mean ± S.D. of three experiments performed in triplicate. Nonlinear reg
significance level compared with FRO pLKO.1. (C) IC50, inhibitory concentr
as IC50 FRO pLKO.1 /IC50 FRO shHMGA1 cell line.than cells in which the HMGA1 expression was stably si-
lenced (Figure 3B).
We analyzed the apoptotic rate in GEO CR and GEO CR
shHMGA1 cells after exposure to 5FU. Drug-induced
apoptosis and caspase 3/7 activation were higher in GEO
CR shHMGA1 cells than in GEO CR cells (Figure 4A). A
similar result was obtained when FRO and FRO shHMGA1
cells were exposed to doxorubicin. Indeed, the apoptotic
rate was higher in the FRO shHMGA1 cells in which
HMGA1 was silenced than in FRO expressing high
HMGA1 levels. Interestingly, procaspase 3 expression de-
creased earlier in GEO CR shHMGA1 and FRO shHMGA1
cells than in the cells overexpressing HMGA1 after treat-
ment with 5FU and doxorubicin, respectively (Figure 4B).
Overexpression of HMGA1 correlates with activation of
the prosurvival pathway
Resistance to gemcitabine in pancreatic adenocarcinoma
cells is mediated by overexpression of HMGA1 throughnd LBH-589. (A) Western Blot analysis of FRO cells and FRO stably
GA1) or with empty vector (FRO pLKO.1) using HMGA1 and β-actin
sis of HMGA1 mRNA in FRO pLKO.1 and FRO shHMGA1cells. Relative
levels between FRO pLKO.1 and FRO shHMGA1cells, normalized with
t Panel). The error bars represent the mean ± S.D. of three independent
nd FRO shHMGA1 cells treated with doxorubicin (Left Panel) or
and absorbance at 490 nm was measured after 72 hours. Values are
ression lines were calculated using GraphPad Prism5. *p < 0.05
ation that kills 50% of cell population and Resistance index calculated
Figure 4 Silencing of HMGA1 triggers caspase activation in response to antineoplastic drugs. (A) Cells were treated with 50 μM of
5-fluorouracil (left panel) or with 500 nM of doxorubicin (right panel) and collected at the indicated time points after drug treatment. The
uncleaved procaspase-3 was detected by Western blot analysis using a specific antibody. Data were normalized with β-actin expression.
(B) Colorimetric caspase 3/7 activity assay, performed on GEO CR pLKO.1 and GEO CR shHMGA1 treated with 50 μM of 5-fluorouracil (left panel)
and on FRO pLKO.1 and FRO shHMGA1(right panel) treated with 500 nM of doxorubicin and harvested 6 h after the treatment. Values are the
mean ± S.D. of three experiments performed in triplicate. *p < 0.05 versus cells transfected with empty vector (GEO CR pLKO.1 or FRO pLKO.1).
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a dominant Akt construct abrogated the HMGA1-
induced increase in chemoresistance to gemcitabine [6].
Therefore, we analyzed the effect of HMGA1-silencing
on the Akt pathway in GEO CR cells treated with 5FU.
As shown in Figure 5, levels of phospho-Akt and of its
downstream effector phospho-p70 were lower in 5FU-
treated GEO CR shHMGA1 cells than in GEO CR cells
overexpressing HMGA1. Conversely, total Akt protein
levels remained unchanged. The same results were ob-
tained in FRO and FRO shHMGA1cells treated with
doxorubicin (Figure 5A).
Subsequently, to define the role of the PI3-K/Akt path-
way in the antineoplastic drug resistance of cancer cells
overexpressing HMGA1, we silenced Akt with a shRNA
in GEO CR and FRO cells overexpressing HMGA1. We
then treated these cells with increasing doses of 5FU or
doxorubicin, and assessed their viability 72 hours later.
As shown in Figure 5B, inhibition of Akt protein synthe-
sis reversed the chemoresistance induced by HMGA1
overexpression. Thus, HMGA1-induced resistance de-
pends on Akt signaling.
Overexpression of HMGA1 correlates with activation of
the DNA-damage response
We previously demonstrated that HMGA proteins en-
hance cancer cell resistance to genotoxic agents by pro-
moting ATM expression and the cellular response to
DNA damage, thereby shifting ATM signaling from celldeath to cell survival [7]. Therefore, we analyzed the
phosphorylation status of ATM and its downstream ef-
fector γH2AX in GEO CR cells treated with 5FU. As
shown in Figure 6A, phospho-ATM and phospho-H2AX
levels were lower in the 5FU-HMGA1-silenced cells
than in 5FU-treated GEO CR cells. Similarly, phospho-
ATM and phospho-H2AX levels were lower in FRO
shHMGA1 cells treated with doxorubicin than in FRO
cells.
To verify that the absence of HMGA1 expression re-
sults in accumulation of DNA damage and enhanced
sensitivity to antineoplastic drugs, we pretreated cells
overexpressing HMGA1 with KU-55933, a specific in-
hibitor of ATM, and, 1 hour later, we treated them with
increasing doses of 5FU or doxorubicin. The cytotoxic
effect of the chemotherapeutic agents was higher in
GEO CR and FRO cells treated with KU-55933 than in
cells treated with 5FU or doxorubin (Figure 6B).
It is known that EGFR stimulate DSB repair after irradi-
ation or activation by its ligands [13] and that the ability of
tumor cells to repair DNA damage is reduced following
EGFR blockade with Cetuximab [14]. Then, to test whether
HMGA1 was able to affect DSB repair after CTX exposure,
GEO CR cells expressing or not HMGA1 were treated with
CTX, and a comet assay was performed to evaluate the
DNA-repair ability following drug exposure. Cells were
collected after 0, 18 and 24 hours of treatment and the
amount of damaged DNA in each cell type was analyzed
evaluating the comet tail moment as a measure of the
Figure 5 Overexpression of HMGA1 correlates with the activation of prosurvival pathway. (A) Cells were treated with 50 μM of
5-fluorouracil (left panel) or with 500 nM of doxorubicin (right panel) and collected at the indicated time points after drug treatment. Protein
extracts were analyzed western blot to evaluate Akt and p70 phosphorylation. Total Akt levels are also reported. β-Actin was reported as western
blot loading control. (B) Cell viability curve of GEO CR and FRO transfected with a short hairpin RNA targeting the Akt gene or with a control
short hairpin RNA and, after 24 hours of transfection, treated with the indicated doses of 5FU or doxorubicin. Values are the mean ± S.D. of three
experiments performed in triplicate. *p < 0.05 versus cells transfected with empty vector (GEO CR pLKO.1 or FRO pLKO.1).
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higher levels of DNA damage after exposure to CTX for
18 hours, compared with GEO CR empty vector. More-
over, after 24 hours HMGA-overexpressing cells were able
to almost completely repair the damage, while HMGA-
silenced cells still showed significant levels of damaged
DNA (Figure 6C).
These data suggest that DSB repair ability is affected
by the presence of HMGA1 proteins also after CTX
treatment.
Discussion
Overexpression of HMGA1 and HMGA2 is a general fea-
ture of experimental and human malignancies and their
overexpression is often correlated with aggressiveness, re-
sistance to conventional anti-cancer therapies and poor
prognosis [3].
In this study we have evaluated the role of HMGA1 pro-
teins in resistance to both conventional and biological anti-
neoplastic drugs. We found that enforced overexpressionof HMGA1 in human colon carcinoma cells GEO, sensitive
to CTX and expressing low levels of HMGA1, promoted
resistance to CTX and 5FU. Conversely HMGA1-silencing
on GEO CR cells abrogated resistance to the above indi-
cated drugs. Similar findings were obtained with FRO cells
expressing high HMGA1 levels treated with doxorubicin
and LBH589. Accordingly, the HMGA1-silenced cells dis-
played a higher apoptotic rate and caspase 3/7 activation
after exposure to 5FU or doxorubicin. This result is con-
sistent with our previous data showing that the block of
HMGA1 expression obtained by using an adenovirus car-
rying the HMGA1 cDNA in antisense orientation leads
thyroid carcinoma cells to apoptotic death [15].
To determine the mechanisms by which HMGA1 pro-
motes drug resistance, we analyzed the Akt-dependent
prosurvival signaling. Indeed, previous findings demon-
strate that HMGA1 overexpression mediates gemcitabine
resistance in pancreatic adenocarcinoma cells through an
Akt-dependent mechanism [6], and over-activation of Akt
pathway is a poor prognostic factor in cancer [16]. Here,
Figure 6 Overexpression of HMGA1 correlates with the activation of DNA-damage response. (A) Cells were treated with 50 μM of
5-fluorouracil (left panel) or with 500 nM of doxorubicin (right panel) and collected at the indicated time points after drug treatment. Protein
extracts were analyzed western blot to evaluate ATM and H2AX phosphorylation. Total ATM levels are also reported. For H2AX loading control
see the β-actin panels in Figure 4. (B) Cell viability curve of GEO CR and FRO cells pretreated or not with 10 μM of KU-55933 for 1 hour, and then
with increasing doses of 5FU or doxorubicin. Values are the mean ± S.D. of three experiments performed in triplicate. (C) GEO CR pLKO.1 and
GEO CR shHMGA1 cells were treated with 1 μM of CTX, collected after 0, 18 and 24 hours of treatment and processed for comet assay. Comets
were stained with SYBR Green, visualized by fluorescence microscopy and analyzed by COMET Score software. A representative comet for each
experimental point is shown in the left panel. Right panel shows the quantitative analysis using the COMET Score software. *p < 0.05 significance
level compared with GEO CR pLKO.1.
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silencing inhibits activation of the Akt pathway after treat-
ment with 5FU or doxorubicin.
We next investigated whether the reduced sensitivity of
the HMGA1-overexpressing cells was associated with en-
hancement of the DNA-damage response, since we previ-
ously demonstrated that HMGA1 positively regulates
cellular levels of ATM in anaplastic thyroid cancer cells so
causing reduced sensitivity to genotoxic agents [7]. Func-
tional interactions have been identified between ATM and
growth factor-mediated signaling [17]. In fact, ATM is a
nuclear protein kinase that functions as a signal transducerin response to DNA damage, but has also a cytoplasmic
localization mediating the activation of Akt through a
growth factor-mediated signaling pathway [18]. Therefore,
the decreased ATM levels in the presence of HMGA1
overexpression might increase pro-survival Akt signaling
after treatment of the cancer cells with the antineoplastic
drugs.
It has been reported that stimulation of EGFR after ir-
radiation or activation by its ligands, such as EGF or
TGFalpha activate DSB repair [13]. The ability of tumor
cells to repair DNA damage is reduced following EGFR
blockade with Cetuximab [14], and recently it has been
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and DNA damage-induced therapy increases in vitro and
in vivo response of human tumor cells [19].
Here, we report that the ability of GEO CR cells, resist-
ant to CTX, to repair DNA damage is reduced in absence
of HMGA1 proteins. These data support the idea that
HMGA1, inducing an overactivation of DNA damage re-
sponse, makes less effective the blockade of this pathway
by CTX. This mechanism could act in combination with
the overactivation of PI3K/AKT prosurvival pathway,
widely reported upregulated in CTX-resistant cells [20].
Conclusions
In conclusion, our findings suggest that the block of
HMGA1 proteins could increase the sensitivity of cancer
cells to antineoplastic drugs by inhibiting the survival sig-
nal and DNA damage repair pathways, the overactivation
of which is a hallmark of resistance to anticancer therapies
and a poor prognostic factor in cancer progression. There-
fore, the targeted suppression or inactivation of HMGA1
could be a potential therapeutic strategy with which to in-
crease chemosensitivity in cancer cells.
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